Lady Mireille is the Founder, President, CEO & Executive Chair of HUYABIO International and has grown this privately held company to become the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective, and lowerrisk drug development in international markets. Through this model she developed and commercialized, in less than 6 years for the Japanese market, HIYASTA a drug for the treatment for lymphoma.
A visionary leader with more than 25 years of proven scientific, clinical, and operational expertise and leadership in the industry she has also made significant contributions to neurological and neurodegenerative disease research including a focus on neuroactive steroids.
She was the first woman to be appointed to the Board of Quintiles, post privatization, now IQVIA, a Fortune 500 company; she is Co-founder and nonExecutive Vice Chair of GHO Capital, a European private equity fund specializing in global health opportunities; is President of GF Management.
She has been bestowed an Honorary degree by the University of Exeter in 2017, and by Concordia University in 2022, for her business, scientific and philanthropic achievements. The UK Sunday Times has twice named her as one of the top 10 women entrepreneurs.
Educated in Canada, the Netherlands, France, and the USA she has a PhD from Radboud University, Nijmegen and post-doctoral fellowships at Bordeaux University and Scripps Institute. Lady Mireille is fluent in English, Dutch, French and Spanish.
